Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672670 | 0.92 | USP30 (0.49) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL15170539 | 0.92 | USP30 (0.49) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL24392051 | 0.85 | GPR119 (0.53) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL1182635 | 0.85 | GPR119 (0.51) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL31691545 | 0.84 | DDB1 (0.44) | HPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL56423 | 0.84 | HPGD (0.50) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL29181777 | 0.83 | HPGD (0.47) | RECQLHPGDGPR119EPHX1 | |
| SCHEMBL4711418 | 0.80 | HPGD (0.55) | RECQLHPGDGPR119USP2SMN1; SMN2 | |
| SCHEMBL18418307 | 0.80 | MGLL (0.71) | RECQLUSP2SMN1; SMN2MGLL | |
| SCHEMBL24393339 | 0.80 | GPR119 (0.47) | RECQLHPGDGPR119EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176237-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009004356-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | NR0B2, NR0B1, NR2E1 | RECQL 1687/4885HPGD 1239/4885GPR119 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.